Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 10;5(10):218-222.
doi: 10.46234/ccdcw2023.040.

Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study - Hohhot City, Inner Mongolia Autonomous Region, China, 2022

Shujie Si  1 , Canrui Jin  2 , Jianping Li  2 , Yunlong Cao  3   4 , Biao Kan  5 , Feng Xue  6 , Xiaoliang Sunney Xie  3   4 , Liang Fang  2 , Gang Zeng  2 , Shuo Zhang  7 , Yaling Hu  6 , Xiaoping Dong  5   8   9   10
Affiliations

Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study - Hohhot City, Inner Mongolia Autonomous Region, China, 2022

Shujie Si et al. China CDC Wkly. .

Abstract

What is already known about this topic?: The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron sub-variants in vitro studies.

What is added by this report?: This study demonstrated the safety and effectiveness of SA58 Nasal Spray against coronavirus disease 2019 (COVID-19) infection in medical personnel for the first time.

What are the implications for public health practice?: This study provides an effective approach for the public to reduce their risk of COVID-19 infection. The findings of this research have the potential to significantly reduce the risk of infection and limit human-to-human transmission in the event of a COVID-19 outbreak.

Keywords: Broad-Spectrum Neutralizing Antibody; COVID-19; Medical Personnel; SA58 Nasal Spray.

PubMed Disclaimer

Conflict of interest statement

X. Xie and Y. Cao are the inventors of the provisional patent applications for the anti-COVID-19 monoclonal antibody (SA58), which has been transferred to Sinovac Life Sciences Co., Ltd. for clinical development. C. Jin, J. Li, G. Zeng, and L. Fang are employees of Sinovac Biotech Co., Ltd., while F. Xue and Y. Hu are employees of Sinovac Life Sciences Co., Ltd. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
Study design and procedures of SA58 Nasal Spray in medical personnel.
Figure 2
Figure 2
Cumulative coronavirus disease 2019 (COVID-19) cases in the drug group and the control group over a 30-day observation period, 2022.
Figure 3
Figure 3
Incidence of reported adverse events (AEs) in the drug group during the 30-day observation.
See this image and copyright information in PMC

References

    1. Castro Dopico X, Ols S, Loré K, Karlsson Hedestam GB Immunity to SARS-CoV-2 induced by infection or vaccination. J Intern Med. 2022;291(1):32–50. doi: 10.1111/joim.13372. - DOI - PMC - PubMed
    1. Cao YL, Yisimayi A, Jian FC, Song WL, Xiao TH, Wang L, et al BA. 2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608(7923):593–602. doi: 10.1038/s41586-022-04980-y. - DOI - PMC - PubMed
    1. Cao YL, Wang J, Jian FC, Xiao TH, Song WL, Yisimayi A, et al Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–63. doi: 10.1038/s41586-021-04385-3. - DOI - PMC - PubMed
    1. Cao YL, Su B, Guo XH, Sun WJ, Deng YQ, Bao LL, et al Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. 2020;182(1):73–84.e16. doi: 10.1016/j.cell.2020.05.025. - DOI - PMC - PubMed
    1. Cao YL, Jian FC, Zhang ZY, Yisimayi A, Hao XH, Bao LL, et al Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Rep. 2022;41(12):111845. doi: 10.1016/j.celrep.2022.111845. - DOI - PMC - PubMed

LinkOut - more resources